Skip to Content

Rule

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of a New Animal Drug Application; Change of Sponsor; Change of Sponsor's Address

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during September and October 2016. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect changes of sponsorship of several applications and a change of a sponsor's address.

DATES:

This rule is effective February 24, 2017, except for the amendment to 21 CFR 524.1465, which is effective March 6, 2017.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5689, george.haibel@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Approval Actions

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during September and October 2016, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Start Printed Page 11507Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm.

Table 1—Original and Supplemental NADAs and ANADAs Approved During September and October 2016

Approval dateFile No.SponsorProduct nameSpeciesEffect of the action/indications for usePublic documents
October 26, 2016141-465Elanco US Inc, 2500 Innovation Way, Greenfield, IN 46140INTEPRITY (avilamycin) and COBAN (monensin) Type C medicated feedsChickensOriginal approval for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler chickens; and as an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maximaFOI Summary.
September 8, 2016200-592Putney, Inc., One Monument Sq., Suite 400, Portland, ME 04101Amoxicillin Trihydrate and Clavulanate Potassium TabletsDogsOriginal approval of a generic copy of NADA 055-099FOI Summary.

II. Change of Sponsorship

Sogeval S. A., 200 Avenue de Mayenne, 53000 Laval, France has informed FDA that it has transferred ownership of, and all rights and interest in, the following applications to Ceva Sante Animale, 10 Avenue de la Ballastière, 33500 Libourne, France:

File No.Product name21 CFR section
099-667IMPOSIL (iron heptomer) Injection522.1182
110-399GLEPTOSIL (gleptoferron) Injection522.1055

Following these changes of sponsorship, Sogeval S. A. is no longer the sponsor of an approved NADA. Accordingly, the firm's name, address, and drug labeler code are being removed from § 510.600(c) (21 CFR 510.600(c)).

In addition, Zoetis, Inc., 333 Portage St., Kalamazoo, MI 49007 has informed FDA that it has transferred ownership of, and all rights and interest in, the following applications to Kinetic Technologies, LLC, 961 Beasley St., Suite 270, Lexington, KY 40509:

File No.Product name21 CFR section
006-417RECOVR (tripelennamine hydrochloride) Injection522.2615
032-319FUROX (furazolidone) Aerosol Powder524.1005
038-838ROBAXIN-V (methocarbamol) Injection522.1380
108-687PET DERM III (dexamethasone) Tablets520.540c
111-369Dexamethasone Sterile Solution522.540

Following these changes of sponsorship, Kinetic Technologies, LLC is now the sponsor of an approved NADA. Accordingly, the firm's name, address, and drug labeler code are being added to § 510.600(c).

III. Withdrawals of Approval

In addition, Putney, Inc., One Monument Square, Suite 400, Portland, ME 04101 has requested that FDA withdraw approval of ANADA 200-524 for Mupirocin Ointment 2% because the product is no longer manufactured or marketed.

Elsewhere in this issue of the Federal Register, FDA gave notice that approval of ANADA 200-524, and all supplements and amendments thereto, is withdrawn, effective March 6, 2017. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect this voluntary withdrawal of approval.

IV. Technical Amendments

Wildlife Laboratories, Inc., 1401 Duff Dr., Suite 600, Fort Collins, CO 80524 has informed FDA that it has changed its address to 1230 W. Ash St., Suite D, Windsor, CO 80550. In addition, FDA has noticed that a sponsor name in § 510.600 does not reflect the particular punctuation used in this sponsor's applications and other correspondence. At this time, we are amending the list of sponsors of approved applications in § 510.600(c) to reflect this change of sponsor address and sponsor's punctuation.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

21 CFR Part 510

  • Administrative practice and procedure
  • Animal drugs
  • Labeling
  • Reporting and recordkeeping requirements

21 CFR Parts 520, 522, and 524

  • Animal drugs

21 CFR Part 558

  • Animal drugs
  • Animal feeds
End List of Subjects Start Printed Page 11508

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, and 558 are amended as follows:

Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for part 510 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority
[Amended]
Start Amendment Part

2. Revise § 510.600 as follows:

End Amendment Part Start Amendment Part

a. In the table in paragraph (c)(1):

End Amendment Part Start Amendment Part

i. In the entry for “Elanco US, Inc.”, remove “Elanco US, Inc.” and in its place add “Elanco US Inc.”;

End Amendment Part Start Amendment Part

ii. Alphabetically add an entry for “Kinetic Technologies, LLC”;

End Amendment Part Start Amendment Part

iii. Remove the entry for “Sogeval S. A.”; and

End Amendment Part Start Amendment Part

iv. Revise the entry for “Wildlife Laboratories, Inc.”

End Amendment Part Start Amendment Part

b. In the table in paragraph (c)(2):

End Amendment Part Start Amendment Part

i. Numerically add an entry for “051031”;

End Amendment Part Start Amendment Part

ii. Revise the entry for “053923”

End Amendment Part Start Amendment Part

iii. In the entry for “058198”, remove “Elanco US, Inc.” and in its place add “Elanco US Inc.”; and

End Amendment Part Start Amendment Part

iv. Remove the entry for “059120”.

End Amendment Part

The additions and revisions read as follows:

Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(1) * * *

Firm name and addressDrug labeler code
*         *         *         *         *         *         *
Kinetic Technologies, LLC, 961 Beasley St., Suite 270, Lexington, KY 40509051031
*         *         *         *         *         *         *
Wildlife Laboratories, Inc., 1230 W. Ash St., Suite D, Windsor, CO 80550053923
*         *         *         *         *         *         *

(2) * * *

Drug labeler codeFirm name and address
*         *         *         *         *         *         *
051031Kinetic Technologies, LLC, 961 Beasley St., Suite 270, Lexington, KY 40509.
*         *         *         *         *         *         *
053923Wildlife Laboratories, Inc., 1230 W. Ash St., Suite D, Windsor, CO 80550.
*         *         *         *         *         *         *
Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for part 520 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. In § 520.88g, in paragraph (b), remove “No. 054771” and in its place add “Nos. 026637 and 054771”.

End Amendment Part
[Amended]
Start Amendment Part

5. In § 520.540c, in paragraph (b), remove “054771” and in its place add “051031”.

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

6. The authority citation for part 522 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

7. In § 522.540, in paragraph (d)(2)(i), remove “054771” and in its place add “051031”.

End Amendment Part
[Amended]
Start Amendment Part

8. In § 522.1055, in paragraph (b), remove “059120” and in its place add “013744”.

End Amendment Part
[Amended]
Start Amendment Part

9. In § 522.1182, in paragraph (b)(3), remove “059120” and in its place add “013744”.

End Amendment Part
[Amended]
Start Amendment Part

10. In § 522.1380, in paragraph (b), remove “054771” and in its place add “051031”.

End Amendment Part
[Amended]
Start Amendment Part

11. In § 522.2615, in paragraph (b), remove “054771” and in its place add “051031”.

End Amendment Part Start Part

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

12. The authority citation for part 524 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

13. In § 524.1005, in paragraph (b)(1), remove “054771” and in its place add “051031”.

End Amendment Part
[Amended]
Start Amendment Part

14. Effective March 6, 2017, in § 524.1465, in paragraph (b), remove “026637”.

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

15. The authority citation for part 558 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371.

End Authority Start Printed Page 11509 Start Amendment Part

16. In § 558.68, revise paragraph (e)(1)(ii) to read as follows:

End Amendment Part
Avilamycin.
* * * * *

(e) * * *

(1) * * *

Avilamycin in grams/tonCombination in grams/tonIndications for useLimitationsSponsor
*         *         *         *         *         *         *
(ii) 13.6 to 40.9Monensin 90 to 110; as provided by No. 058198 in § 510.600(c) of this chapterBroiler chickens: For the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler chickens; and as an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maximaFeed as the sole ration for 21 consecutive days. To assure responsible antimicrobial drug use in broiler chickens, treatment administration must begin on or before 10 days of age. See § 558.355(d) of this chapter for additional required labeling058198
* * * * *
Start Signature

Dated: February 21, 2017.

Leslie Kux,

Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2017-03677 Filed 2-23-17; 8:45 am]

BILLING CODE 4164-01-P